Sacubitril/Valsartan Versus Valsartan in Heart Failure
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure focused on measuring LVEF%,, Lipo A,, troponin I,, NT-Pro BNP,, neopterin
Eligibility Criteria
Inclusion Criteria: Patients with HF were enrolled if aged > 35 years, Stable symptomatic systolic chronic HF (≥ 4 weeks), with left ventricular ejection fraction (LVEF) < 35%, NYHA class II-III, Sinus rhythm and resting HR ≥ 70 beats/min on optimised standard medical therapy. Exclusion Criteria: Patients with acute decompensation, Cerebrovascular events during the previous 6 months, Pregnancy, breastfeeding, Any valve dysfunction/abnormality, Active myocarditis, Second-degree and third-degree atrioventricular block, Sick sinus syndrome.
Sites / Locations
- Tanta University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group 1 (N = 40)
Group 2 (N = 40)
Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) in addition to recommended therapy according to physician's judgment.
group 2 received valsartan (target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.